These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma. De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682 [TBL] [Abstract][Full Text] [Related]
3. The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia. Schack LH; Mouritsen LS; Elowsson C; Krarup-Hansen A; Safwat A Acta Oncol; 2015 Jan; 54(1):34-40. PubMed ID: 25263179 [TBL] [Abstract][Full Text] [Related]
4. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma. Simpson EL; Rafia R; Stevenson MD; Papaioannou D Health Technol Assess; 2010 May; 14 Suppl 1():63-7. PubMed ID: 20507805 [TBL] [Abstract][Full Text] [Related]
5. Trabectedin in soft tissue sarcomas. Petek BJ; Loggers ET; Pollack SM; Jones RL Mar Drugs; 2015 Feb; 13(2):974-83. PubMed ID: 25686274 [TBL] [Abstract][Full Text] [Related]
6. What makes real world outcomes in soft tissue sarcomas? A mono-institutional trabectedin experience. Moriceau G; Vallard A; Méry B; Rivoirard R; Langrand-Escure J; Espenel S; Ben Mrad M; Wang G; Diao P; Fournel P; Collard O; Magné N Bull Cancer; 2015 Oct; 102(10):814-22. PubMed ID: 26384694 [TBL] [Abstract][Full Text] [Related]
7. Trabectedin for advanced soft tissue sarcomas: a single institution experience. Gounaris I; Hatcher HM; Davidson D; Sherbourne K; Alam S; Zaki KA; Horan G; Earl HM Future Oncol; 2014 Aug; 10(11):1843-51. PubMed ID: 24450573 [TBL] [Abstract][Full Text] [Related]
8. Body Mass Index as a Risk Factor for Toxicities in Patients with Advanced Soft-Tissue Sarcoma Treated with Trabectedin. Vincenzi B; Badalamenti G; Armento G; Silletta M; Spalato Ceruso M; Catania G; Napolitano A; Maltese G; Valeri S; Incorvaia L; Santini D; Tonini G Oncology; 2018; 95(1):1-7. PubMed ID: 29510410 [TBL] [Abstract][Full Text] [Related]
9. Trabectedin in patients with metastatic soft tissue sarcoma: a retrospective single center analysis. Schur S; Lamm W; Köstler WJ; Hoetzenecker K; Nemecek E; Schwameis K; Klepetko W; Windhager R; Brodowicz T Anticancer Drugs; 2013 Aug; 24(7):725-30. PubMed ID: 23728219 [TBL] [Abstract][Full Text] [Related]
11. Experience of the use of trabectedin (ET-743, Yondelis) in 21 patients with pre-treated advanced sarcoma from a single centre. Roylance R; Seddon B; McTiernan A; Sykes K; Daniels S; Whelan J Clin Oncol (R Coll Radiol); 2007 Oct; 19(8):572-6. PubMed ID: 17624747 [TBL] [Abstract][Full Text] [Related]
12. Trabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centers. Sanfilippo R; Grosso F; Jones RL; Banerjee S; Pilotti S; D'Incalci M; Dei Tos AP; Raspagliesi F; Judson I; Casali PG Gynecol Oncol; 2011 Dec; 123(3):553-6. PubMed ID: 21917307 [TBL] [Abstract][Full Text] [Related]
13. Trabectedin for metastatic soft tissue sarcoma: a retrospective single center analysis. Schmitt T; Keller E; Dietrich S; Wuchter P; Ho AD; Egerer G Mar Drugs; 2010 Oct; 8(10):2647-58. PubMed ID: 21116412 [TBL] [Abstract][Full Text] [Related]
14. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer. Carter NJ; Keam SJ Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287 [TBL] [Abstract][Full Text] [Related]
15. Retrospective inter- and intra-patient evaluation of trabectedin after best supportive care for patients with advanced translocation-related sarcoma after failure of standard chemotherapy. Araki N; Takahashi S; Sugiura H; Ueda T; Yonemoto T; Takahashi M; Morioka H; Hiraga H; Hiruma T; Kunisada T; Matsumine A; Kawai A Eur J Cancer; 2016 Mar; 56():122-130. PubMed ID: 26845175 [TBL] [Abstract][Full Text] [Related]
16. Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG). Kasper B; Reichardt P; Pink D; Sommer M; Mathew M; Rauch G; Hohenberger P Mar Drugs; 2015 Jan; 13(1):379-88. PubMed ID: 25591040 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. Demetri GD; Chawla SP; von Mehren M; Ritch P; Baker LH; Blay JY; Hande KR; Keohan ML; Samuels BL; Schuetze S; Lebedinsky C; Elsayed YA; Izquierdo MA; Gómez J; Park YC; Le Cesne A J Clin Oncol; 2009 Sep; 27(25):4188-96. PubMed ID: 19652065 [TBL] [Abstract][Full Text] [Related]
18. Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. Le Cesne A; Ray-Coquard I; Duffaud F; Chevreau C; Penel N; Bui Nguyen B; Piperno-Neumann S; Delcambre C; Rios M; Chaigneau L; Le Maignan C; Guillemet C; Bertucci F; Bompas E; Linassier C; Olivier T; Kurtz JE; Even C; Cousin P; Yves Blay J; Eur J Cancer; 2015 Apr; 51(6):742-50. PubMed ID: 25727882 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of trabectedin for the treatment of liposarcoma. Zijoo R; von Mehren M Expert Opin Pharmacother; 2016 Oct; 17(14):1953-62. PubMed ID: 27615729 [TBL] [Abstract][Full Text] [Related]
20. Prolonged disease stability with trabectedin in two monorenal patients with retroperitoneal sarcoma. Bruder F; Massa D; Barca M; Contu V; Airoldi M; Crova A Tumori; 2014; 100(3):e63-6. PubMed ID: 25076252 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]